Bayer faces EUR 0.41 estimate before results: Bayer stock gains 1.58 percent

Published on 10/15/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock costs EUR 45.78 on October 15, 2026 versus EUR 45.07 at Xetra. Q2 sales rose 2.20 percent to EUR 10.87 billion.

Earnings pressure and regulatory progress

Analysts placed expected earnings per share at EUR 0.41 on October 15, 2026, down from EUR 0.52 in August.
Second-quarter sales rose 2.20 percent to EUR 10.87 billion, while adjusted EBITDA increased 1.90 percent to EUR 2.14 billion.
Bayer stock trades at EUR 45.78 at 9:46 a.m. CEST at Lang & Schwarz on October 15, 2026, 1.58 percent above the Xetra close of October 14, 2026.
Bayer will publish third-quarter results on November 3, 2026, at 7:30 a.m. CET.

Makrofotografie von weißen runden Tabletten in extremer Nahaufnahme — Bayer AG (DE000BAY0017): Makroaufnahme weißer runder Tabletten mit scharfer Tiefenschärfe und feiner Oberflächentextur, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 45.78 at Lang & Schwarz on October 15, 2026 at 9:46 a.m. CEST, up 1.58 percent versus the Xetra close of October 14, 2026 at EUR 45.07. Aktiencheck reported on October 15, 2026 that expected earnings per share had fallen to EUR 0.41 from EUR 0.52 in August, ahead of Bayer's November 3 results.

Estimate pressure meets a regulatory step

The estimate is not a reported Bayer result. It is a market expectation that the third-quarter report will test, with timing effects in the agricultural business cited as a possible explanation.

On October 8, 2026, Bayer said the U.S. Food and Drug Administration had accepted its supplemental filing for finerenone in chronic kidney disease without diabetes. The filing was supported by the Phase III FIND-CKD study and is not an approval.

Three dates show the changing picture

On September 17, 2026, Boerse Express reported Bayer's second-quarter sales at EUR 10.87 billion, up 2.20 percent, and adjusted EBITDA at EUR 2.14 billion, up 1.90 percent. On October 8, 2026, Bayer announced the accepted finerenone filing. On October 15, 2026, expected earnings per share stood at EUR 0.41, compared with EUR 0.52 in August.

What is the next test?

Bayer will publish its third-quarter results on November 3, 2026, at 7:30 a.m. CET, followed by the earnings call at 2:00 p.m. CET. The report will show whether the lower estimate reflects agricultural timing or broader operating pressure.

Stock price and investor context

Bayer's market capitalization was EUR 44.9 billion on October 15, 2026. The 52-week range was EUR 25.78 to EUR 53.92, placing the current euro quote inside that range. The combination of a regulatory advance and lower earnings expectations gives the November report two distinct benchmarks.

Bayer was trading at EUR 45.78 at Lang & Schwarz on October 15, 2026 at 9:46 a.m. CEST, 1.58 percent above the Xetra close of October 14, 2026 at EUR 45.07. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.